Hoth Therapeutics (HOTH) said Wednesday its therapeutic candidate, HT-001, showed "promising" results in a patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.
The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors, the company said.
"After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks," it said.
The data will be presented at the upcoming American Academy of Dermatology annual meeting, Hoth said. A phase 2A trial of HT-001 in a broader patient population is being conducted.
The shares were over 7% lower in recent trading.
Price: 1.15, Change: -0.10, Percent Change: -7.66
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。